Why Immunotherapy Fails — and How We’re Fixing It
Restoring the immune cell interactions required for durable tumor destruction
Most cancer immunotherapies fail because the immune system is never properly engaged. In many patients, the right immune cells are present — they just aren’t interacting in the way tumor destruction actually requires.
Voyant was built to understand and fix that failure.
Rather than starting with targets or pathways on a certain cell type of interest, we start with mapping immune cell interactions directly inside human tumors. Using spatial intelligence (advanced microscopy and machine learning), we map how immune cells are organized, how they communicate, and which interaction patterns lead to durable tumor regression versus continued growth.
This work led us to identify specific multi-cellular immune “triads” that are required for effective anti-tumor immunity. When these interactions are missing or disrupted, tumors persist. When they are restored, tumors shrink — across multiple solid tumor types.
That insight fundamentally changes how immunotherapies should be built.
Voyant designs multi-specific biologics that re-engage these critical immune interactions, rather than relying on single receptors or pathways. Each molecule is engineered to restore productive communication between immune cells inside the tumor microenvironment, addressing resistance at its root.
Today, we’re excited to open our platform to strategic collaborators. This follows positive readouts from our internal pipeline, validating the technology and enabling broader partnerships.
Through our proprietary spatial intelligence assays in primary human tumor samples, partners can directly measure how their immuno-oncology candidates create, restore, or disrupt these critical immune interactions. This allows teams to de-risk mechanism, optimize molecular design, identify synergistic combinations, and generate clinically relevant biomarker hypotheses — all grounded in human biology rather than proxy models.
For partners, this means clearer mechanistic conviction, sharper clinical strategies, and stronger differentiation in crowded IO landscapes. For Voyant, it accelerates learning while staying tightly aligned with our own pipeline and mission.
We will be attending the J.P. Morgan Healthcare Conference (JPM) in January and welcome the opportunity to discuss potential collaborations with teams developing next-generation immunotherapies. Our platform provides direct, human-relevant insights into mechanisms that drive clinical efficacy.
Related Reading
Well said. What resonates most is the distinction between immune presence and immune interaction. We’ve repeatedly seen that activation and infiltration can coexist with non-response when the underlying cellular coordination inside human tumors is broken. Mapping and restoring those interactions feels like a necessary shift beyond single-target thinking in IO.